{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T04:31:45Z","timestamp":1770438705329,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1053\/j.seminoncol.2013.05.013","type":"journal-article","created":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T23:47:54Z","timestamp":1377215274000},"page":"436-443","source":"Crossref","is-referenced-by-count":18,"title":["Systemic Treatment Options for Untreated Patients With Metastatic Clear Cell Renal Cancer"],"prefix":"10.1053","volume":"40","author":[{"given":"Ana M.","family":"Molina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Motzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Y.","family":"Heng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.seminoncol.2013.05.013_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1053\/j.seminoncol.2013.05.013_bib2","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0094-0143(03)00056-9","article-title":"Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease","volume":"30","author":"Janzen","year":"2003","journal-title":"Urol Clin North Am"},{"issue":"2","key":"10.1053\/j.seminoncol.2013.05.013_bib3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1053\/j.seminoncol.2013.05.013_bib4","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9637","key":"10.1053\/j.seminoncol.2013.05.013_bib5","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"issue":"22","key":"10.1053\/j.seminoncol.2013.05.013_bib6","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2013.05.013_bib7","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","article-title":"Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206","volume":"26","author":"Rini","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.05.013_bib8","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal-cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"10.1053\/j.seminoncol.2013.05.013_bib9","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminoncol.2013.05.013_bib10","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.hoc.2011.04.003","article-title":"Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far","volume":"25","author":"Tang","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"issue":"3","key":"10.1053\/j.seminoncol.2013.05.013_bib11","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/01.ju.0000110610.61545.ae","article-title":"Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis","volume":"171","author":"Flanigan","year":"2004","journal-title":"J Urol"},{"issue":"1","key":"10.1053\/j.seminoncol.2013.05.013_bib12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminoncol.2013.05.013_bib13","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1200\/JCO.2005.05.179","article-title":"Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma","volume":"23","author":"Mekhail","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.05.013_bib14","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/annonc\/mdf257","article-title":"Prognostic facotrs of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie","volume":"13","author":"Negrier","year":"2002","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1053\/j.seminoncol.2013.05.013_bib15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.eururo.2008.12.026","article-title":"Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients","volume":"57","author":"Naito","year":"2010","journal-title":"Eur Urol"},{"issue":"34","key":"10.1053\/j.seminoncol.2013.05.013_bib16","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.05.013_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","author":"Heng","year":"2013","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1053\/j.seminoncol.2013.05.013_bib18","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1053\/j.seminoncol.2013.05.013_bib19","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","article-title":"Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival","volume":"28","author":"Escudier","year":"2010","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1053\/j.seminoncol.2013.05.013_bib20","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","article-title":"Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206","volume":"28","author":"Rini","year":"2010","journal-title":"J Clin Oncol"},{"issue":"suppl 9","key":"10.1053\/j.seminoncol.2013.05.013_bib21","article-title":"Randomized phase IIIB trial of temsirolimus and bevacizumab versus interferon and bevacizumab in metastatic renal cell carcinoma: results from INTORACT","volume":"23","author":"Rini","year":"2012","journal-title":"37th Congress of the European Society for Medical Oncology. 2012. Ann Oncol"},{"key":"10.1053\/j.seminoncol.2013.05.013_bib22","first-page":"289","author":"Motzer","year":"2002","journal-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol"},{"issue":"suppl 9","key":"10.1053\/j.seminoncol.2013.05.013_bib23","article-title":"Randomized, open label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (mRCC): results of the COMPARZ trial","volume":"23","author":"Motzer","year":"2012","journal-title":"37th Congress of the European Society for Medical Oncology. 2012. Ann Oncol"},{"issue":"suppl abstr CRA4502","key":"10.1053\/j.seminoncol.2013.05.013_bib24","article-title":"Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in paitents with metastatic renal cell carcinoma (mRCC)\u2014PISCES study","volume":"30","author":"Escudier","year":"2012","journal-title":"NCT 01064310. J Clin Oncol"},{"issue":"suppl abstr 4501","key":"10.1053\/j.seminoncol.2013.05.013_bib25","article-title":"Tivozanib versus sorefenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial","volume":"30","author":"Motzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.05.013_bib26","doi-asserted-by":"crossref","unstructured":"Molina AM, Motzer RJ. Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma. Clin Genitourinary Cancer. Dec 2008;6 suppl 1:S7-13","DOI":"10.3816\/CGC.2008.s.002"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775413000882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775413000882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,13]],"date-time":"2018-10-13T19:56:38Z","timestamp":1539460598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775413000882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0093775413000882"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2013.05.013","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}